Brentuximab-related apoptotic colopathy.

Suppr

超能文献

作者信息

Parente Paola, Graziano Paolo, Scalzulli Potito, Mastracci Luca, Grillo Federica

机构信息

UOC di Anatomia Patologica, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, FG, Italy.

SC di Ematologia, Fondazione IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, FG, Italy.

出版信息

Pathology. 2020 Jun;52(4):483-484. doi: 10.1016/j.pathol.2020.02.011. Epub 2020 Apr 25.

DOI:10.1016/j.pathol.2020.02.011

PMID:32345520

Abstract

摘要

相似文献

Pathology. 2020 Jun;52(4):483-484. doi: 10.1016/j.pathol.2020.02.011. Epub 2020 Apr 25.

FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?美国食品药品监督管理局和欧洲药品管理局批准 Brentuximab Vedotin 用于治疗晚期霍奇金淋巴瘤：另一个市场参与者？

Eur J Haematol. 2019 Sep;103(3):145-151. doi: 10.1111/ejh.13269. Epub 2019 Jun 17.

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.本妥昔单抗维布妥昔单抗、多柔比星、长春碱和达卡巴嗪治疗非肿块型局限期经典霍奇金淋巴瘤。

Blood. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. Epub 2019 Jun 11.

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.本妥昔单抗联合纳武利尤单抗用于老年或不符合化疗条件的霍奇金淋巴瘤患者的一线治疗（ACCRU）：一项多中心、单臂、2期试验

Lancet Haematol. 2020 Nov;7(11):e808-e815. doi: 10.1016/S2352-3026(20)30275-1. Epub 2020 Oct 1.

Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.与维布妥昔单抗治疗相关的严重进行性鸟分枝杆菌复合群感染

J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373. doi: 10.1093/jpids/piy109.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.本妥昔单抗联合地塞米松、大剂量阿糖胞苷和顺铂作为复发/难治性经典型霍奇金淋巴瘤挽救治疗的Ⅰ期剂量递增研究：HOVON/LLPC移植BRAVE研究

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31.

Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.抑制多药耐药蛋白1（MDR1）可克服霍奇金淋巴瘤对维布妥昔单抗的耐药性。

Clin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6.

Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.儿童经典型霍奇金淋巴瘤的新型免疫治疗方法：纳武单抗或本妥昔单抗联合AVD方案

Pediatr Blood Cancer. 2024 Aug;71(8):e31091. doi: 10.1002/pbc.31091. Epub 2024 Jun 5.

Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies.本妥昔单抗治疗与急性和慢性炎症性脱髓鞘性多发性神经根神经病相关。

J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):786-788. doi: 10.1136/jnnp-2020-323124. Epub 2020 Apr 23.

Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.本妥昔单抗在一名接受血液透析患者中的成功应用：首例真实病例经验

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):e595-e596. doi: 10.1016/j.clml.2019.07.443. Epub 2019 Aug 30.

引用本文的文献

Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient.非干细胞移植患者中由 Brentuximab 诱发的结肠炎

ACG Case Rep J. 2023 Jan 25;10(1):e00974. doi: 10.14309/crj.0000000000000974. eCollection 2023 Jan.

Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists.与免疫检查点抑制剂治疗相关的乳糜泻样病症的组织学特征：病理学家需牢记的信号

Diagnostics (Basel). 2022 Feb 3;12(2):395. doi: 10.3390/diagnostics12020395.

Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD).非炎症性肠病结肠炎的组织病理学。来自意大利胃肠道研究组（GIPAD）的实用方法。

Pathologica. 2021 Feb;113(1):54-65. doi: 10.32074/1591-951X-234.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验